ERBB2 and gastric cancer: Patients considered for the study are those with GC according to the last AJCC Classification (including Siewert III tumors) with synchronous macroscopic PMs (excluding patients with only positive cytology), with the absence of her2/neu overexpression, and without extraperitoneal metastases.